The Angeles Clinic and Research Institute Among First in the Nation to Treat Advanced Prostate Cancer Patients with PROVENGE
Dear Colleague,
As you know, the Food and Drug Administration recently approved Provenge (Spicucel-T) immunotherapy for the treatment of patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer based on survival advantage.
The Immunotherapeutics program at The Angeles Clinic is pleased to offer this option for your patients with Castration Resistant Prostate Cancer (CRPC) at The Angeles Clinic and Research Institute.
Eligible patients are those who:
(1) Have metastatic prostate
(2) Are refractory to combined androgen blockade
(3) Have bone and lymph node metastases only
(4) Are chemotherapy naieve or
(5) Are 3 months from last chemotherapy
Patients will be seen at our facility for treatment and will be returned for follow-up at your institution.
For further information please contact:
Clinical Therapy - Prostate
(310) 231-2185
The Angeles Clinic and Research Institute Among First in the Nation to Treat Advanced Prostate Cancer Patients with PROVENGE
Dear Colleague,
As you know, the Food and Drug Administration recently approved Provenge (Spicucel-T) immunotherapy for the treatment of patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer based on survival advantage.
The Immunotherapeutics program at The Angeles Clinic is pleased to offer this option for your patients with Castration Resistant Prostate Cancer (CRPC) at The Angeles Clinic and Research Institute.
Eligible patients are those who:
(1) Have metastatic prostate
(2) Are refractory to combined androgen blockade
(3) Have bone and lymph node metastases only
(4) Are chemotherapy naieve or
(5) Are 3 months from last chemotherapy
Patients will be seen at our facility for treatment and will be returned for follow-up at your institution.
For further information please contact:
Clinical Therapy - Prostate
(310) 231-2185